Institution
Tulane University
Education•New Orleans, Louisiana, United States•
About: Tulane University is a education organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Blood pressure. The organization has 24478 authors who have published 47205 publications receiving 1944993 citations. The organization is also known as: University of Louisiana.
Topics: Population, Blood pressure, Receptor, Poison control, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Each EEG coherence method has its own potential sources of error and provides coherence estimates for different neural population sizes located in different locations, so studies of coherence and brain state should include several different kinds of estimates to take full advantage of information in recorded signals.
289 citations
••
TL;DR: The FBN1 mutation database has recently been modified to follow the guidelines on mutation databases of the HUGO Mutation Database Initiative (MDI) and the Human Genome Variation Society (HGVS), including their approved mutation nomenclature.
Abstract: Fibrillin is the major component of extracellular microfibrils. Mutations in the fibrillin gene on chromosome 15 (FBN1) were first described in the heritable connective disorder, Marfan syndrome (MFS). FBN1 has also been shown to harbor mutations related to a spectrum of conditions phenotypically related to MFS, called "type-1 fibrillinopathies." In 1995, in an effort to standardize the information regarding these mutations and to facilitate their mutational analysis and identification of structure/function and phenotype/genotype relationships, we created a human FBN1 mutation database, UMD-FBN1. This database gives access to a software package that provides specific routines and optimized multicriteria research and sorting tools. For each mutation, information is provided at the gene, protein, and clinical levels. This tool is now a worldwide reference and is frequently used by teams working in the field; more than 220,000 interrogations have been made to it since January 1998. The database has recently been modified to follow the guidelines on mutation databases of the HUGO Mutation Database Initiative (MDI) and the Human Genome Variation Society (HGVS), including their approved mutation nomenclature. The current update shows 559 entries, of which 421 are novel. UMD-FBN1 is accessible at www.umd.be/. We have also recently developed a FBN1 polymorphism database in order to facilitate diagnostics.
288 citations
••
San Diego State University1, University of Minnesota2, University of Maryland, College Park3, University of North Carolina at Chapel Hill4, National Institutes of Health5, University of New Mexico6, University of Arizona7, Tulane University8, University of South Carolina9, University of Maryland, Baltimore10
TL;DR: The purpose of the present paper is to describe a SE framework that guided the intervention and measurement plans for a specific study, the trial of activity for adolescent girls, and to suggest elements that can generalize to other health promotion studies.
Abstract: Social–ecological (SE) models are becoming more widely used in health behavior research. Applying SE models to the design of interventions is challenging because models must be tailor-made for each behavior and population, other theories need to be integrated into multilevel frameworks, and empirical research to guide model development is limited. The purpose of the present paper is to describe a SE framework that guided the intervention and measurement plans for a specific study. The trial of activity for adolescent girls (TAAG) is a multi-center study of interventions to reduce the decline of physical activity in adolescent girls. The TAAG framework incorporates operant learning theory, social cognitive theory, organizational change theory and the diffusion of innovation model in a multi-level model. The explicit and practical model developed for TAAG has already benefited the study and may have elements that can generalize to other health promotion studies.
288 citations
••
TL;DR: Tacrolimus-based immunosuppression seems effective for rejection prophylaxis during the first year after cardiac transplantation and is associated with less hypertension and hyperlipidemia and no difference in renal function, hyperglycemia, hypomagnesemia, or hyperkalemia.
Abstract: Background Tacrolimus-based immunosuppression seems safe and effective in liver and kidney transplantation. To assess the safety and efficacy of tacrolimus (TAC)-based immunosuppression after cardiac transplantation as well as the relative impact of tacrolimus on immunosuppression-related side effects such as hypertension and hyperlipidemia, we conducted a prospective, randomized, open-label, multicenter study of otherwise identical tacrolimus- and cyclosporine-based immunosuppressive regimens in adult patients undergoing cardiac transplantation. Methods Eighty-five adult patients (pts) at six United States cardiac transplant centers, undergoing their first cardiac transplant procedure, were prospectively randomized to receive either TAC-based ( n = 39) or cyclosporine (CYA)-based ( n = 46) immunosuppression. All pts received a triple-drug protocol with 15 pts (18%) receiving peri-operative OKT3 to delay TAC/CYA due to pre-transplant renal dysfunction. Endomyocardial biopsies were performed at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 24, and 52. The study duration was 12 months. Results Patients were mostly male (87%) Caucasian (90%) with a mean age of 54 years and primary diagnoses of coronary artery disease (55%) and idiopathic dilated cardiomyopathy (41%). There were no significant demographic differences between groups. Patient and allograft survival were not different in the two groups. The probability and overall incidence of each grade of rejection, whether treated or not, and the types of treatment required did not differ between the groups. At baseline and through 12 months of follow-up, chemistry and hematology values were similar between the groups except serum cholesterol was higher in the CYA group at 3, 6, and 12 months (239 vs 205 mg/dL, 246 vs 191 mg/dL, 212 vs 186 mg/dL, respectively, p p = 0.01). There were no significant differences in renal function, hyperglycemia, hypomagnesemia, or hyperkalemia during the first 12 months. More CYA patients developed new-onset hypertension requiring pharmacologic treatment (71% vs 48%, p = 0.05). The incidence of infection was the same for the two groups (2.6 episodes/pt/12 month follow-up). Conclusion Tacrolimus-based immunosuppression seems effective for rejection prophylaxis during the first year after cardiac transplantation and is associated with less hypertension and hyperlipidemia and no difference in renal function, hyperglycemia or infection incidence when compared to cyclosporine-based immunosuppression.
288 citations
••
Case Western Reserve University1, Utrecht University2, University of California, Davis3, National University of Singapore4, University of Buenos Aires5, London Clinic6, Tulane University7, Erasmus University Rotterdam8, University of L'Aquila9, Deakin University10, Albert Einstein College of Medicine11, Valparaiso University12, University of California, San Francisco13
TL;DR: A new unified definition of PE is offered and best practices treatment recommendations are presented to guide clinicians, both familiar and unfamiliar with PE, in facilitating treatment of their patients.
288 citations
Authors
Showing all 24722 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
JoAnn E. Manson | 270 | 1819 | 258509 |
Frank B. Hu | 250 | 1675 | 253464 |
Eric B. Rimm | 196 | 988 | 147119 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
Nicholas J. White | 161 | 1352 | 104539 |
Tien Yin Wong | 160 | 1880 | 131830 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Joseph Sodroski | 138 | 542 | 77070 |
Glenn M. Chertow | 128 | 764 | 82401 |
Darwin J. Prockop | 128 | 576 | 87066 |
Kenneth J. Pienta | 127 | 671 | 64531 |
Charles Taylor | 126 | 741 | 77626 |